Researchers are looking for a better way to treat heart failure (HF), a condition in which the heart does not pump blood as well as it should. Research has shown that the levels of a hormone called N-terminal proBNP (NT-proBNP) in the body can be used for differential diagnosing of HF. NT-proBNP is released by the heart when there is an increase in heart pressure. The levels of NT-proBNP can indicate whether medical problems are likely to happen due to HF. These medical problems are called "decompensation events." The higher a person's NT-proBNP levels is expected, the higher their risk of developing HF and having decompensation events. So, the researchers in this study want to learn about NT-proBNP levels and decompensation events in German patients with a common type of HF called heart failure with reduced ejection fraction (HFrEF). In patients with HFrEF, the muscle on the left chamber of the heart does not pump blood as well as it should. The researchers will collect information from patients and their health records for about 300 adult patients in Germany with HFrEF who have been receiving standard of care treatment for their condition. Standard of care treatments are treatments that doctors commonly use to treat patients. The researchers will study and record the levels of NT-proBNP levels and any changes in the health of the patients at time of NT-proBNP measurement. The researchers will collect this information between May 2021 and September 2021. The patients in this study : * have had any HF-decompensation event since January 2016 * have had at least 1 NT-proBNP measurement done before the study The researchers will collect the following information about the patients: * the results of NT-proBNP measurements * the date of the NT-proBNP measurements * the number and type of decompensation events
Study Type
OBSERVATIONAL
Enrollment
169
NT-proBNP (N-terminal pro B-type natriuretic) peptide distribution in patients with HFrEF who had a previous decompensation event.
Many locations
Multiple Locations, Germany
Proportion of NT-proBNP < 5314pg/ml
Range of NT-proBNP values and the proportion of NT-proBNP \< 5314pg/ml in patients with HFrEF who had a previous decompensation event. The first NT-proBNP value, will be described via summary statistics, as well as by a frequency table based on categorized NT-proBNP values. The summary statistics as well as the proportion of patients within different NT-proBNP categories (i.e. \</\>=5314pg/ml) will be presented overall and stratified by number of decompensation event during observation period.
Time frame: within 6 months after decompensation event
Range of NT-proBNP values
Range of NT-proBNP values and the proportion of NT-proBNP \< 5314pg/ml in patients with HFrEF who had a previous decompensation event. The first NT-proBNP value, will be described via summary statistics, as well as by a frequency table based on categorized NT-proBNP values. The summary statistics as well as the proportion of patients within different NT-proBNP categories (i.e. \</\>=5314pg/ml) will be presented overall and stratified by number of decompensation event during observation period.
Time frame: within 6 months after decompensation event
Range of NT-proBNP values across demographic characteristics
Demographic characteristics will be described by frequency tables and/or summary statistics. The patients´ medical history conditions will be displayed by a frequency table. Patients with specific prior and concomitant medication will be presented by frequency tables. The standard of care for heart failure treatment (including Beta Blocker, Diuretics, ACEi or ARB, MRA, Sacubitril/Valsartan, ICD, Biventricular Pacemaker) will be tabulated by patient frequencies.
Time frame: within 6 months after decompensation event
Range of NT-proBNP values across clinical patient characteristics
Patient characteristics (e.g. comorbidities, HFH, NYHA class) will be described by frequency tables and/or summary statistics. The patients´ medical history conditions will be displayed by a frequency table. Patients with specific prior and concomitant medication will be presented by frequency tables. The standard of care for heart failure treatment (including Beta Blocker, Diuretics, ACEi or ARB, MRA, Sacubitril/Valsartan, ICD, Biventricular Pacemaker) will be tabulated by patient frequencies.
Time frame: within 6 months after decompensation event
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.